Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Biofrontera Inc(BFRI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BFRI
09/23/2026: BFRI (1-star) is currently NOT-A-BUY. Pass it for now.
Biofrontera Inc. is a specialized biopharmaceutical company focused on the U.S. commercialization of dermatological treatments, most notably Ameluz for actinic keratosis. The company's primary strength lies in its targeted approach to the photodynamic therapy market and its established FDA-approved portfolio. While it has successfully brought a product to market, its investment story is centered on scaling sales and expanding clinical indications to drive growth. Key risks include intense competition from larger pharmaceutical firms, reliance on a single core product, and the need to achieve sustained profitability. This stock may suit investors willing to accept the volatility associated with small-cap biotech, particularly those monitoring product adoption trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through product adoption, but carries risks associated with early-stage commercialization. |
| Momentum investor | Mixed fit | Momentum investment is conditional on sustained revenue growth signals and positive market sentiment. |
| Value investor | Weak fit | The company's lack of consistent profitability makes it less suitable for traditional value-based investment strategies. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses on reinvesting cash flow into commercial operations. |
| Low-risk investor | Weak fit | The inherent volatility of small-cap pharmaceutical stocks is generally unsuitable for low-risk investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap pharmaceutical stocks often experience significant price swings based on clinical or market news. |
| Valuation risk | Medium / high | Determining fair value for companies with developing revenue streams involves significant uncertainty. |
| Competition risk (Large Pharma) | High | The company competes with established firms that have greater resources and market access. |
| Business quality | Medium | The business relies heavily on a limited product portfolio, concentrating operational risk. |
| Dividend income | Low / none | There is no current expectation of income through dividends. |
| Execution risk | Medium / high | Success depends on the effective execution of commercial strategies and market penetration. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -76.8% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.38M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 776.3K shares | Beta 0.84 | 52 Weeks Range 0.55 - 1.66 | Updated Date 09/23/2026 |
52 Weeks Range 0.55 - 1.66 | Updated Date 09/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Dermatological Sales | Revenue generated from the sale of the drug Ameluz for photodynamic therapy. | The company makes money by selling a specialized skin cancer treatment drug to dermatologists. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 13 | Enterprise Value 20.07M | Price to Sales(TTM) 0.38 |
Enterprise Value 20.07M | Price to Sales(TTM) 0.38 | ||
Enterprise Value to Revenue 0.43 | Enterprise Value to EBITDA -0.79 | Shares Outstanding 14.85M | Shares Floating 11.84M |
Shares Outstanding 14.85M | Shares Floating 11.84M | ||
Percent Insiders 11.99 | Percent Institutions 20.72 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Biofrontera Inc
Exchange NASDAQ | Headquarters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 84 | Website https://www.biofrontera-us.com |
Full time employees 84 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.